-
1
المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin
المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Associationمصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test -
2
المؤلفون: James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser
المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test -
3
المؤلفون: Piotr Rutkowski, Alexander C.J. van Akkooi, Michele Maio, Alfonsus J. M. van den Eertwegh, Christian U. Blank, Nageatte Ibrahim, Adnan Khattak, Paolo A. Ascierto, Rahima Jamal, Ralf Gutzmer, Andrew Haydon, Mikhail Lichinitser, Susana Puig, Victoria Atkinson, Mario Mandalà, Sandrine Marreaud, Caroline Robert, Jean-Jacques Grob, Alexander M.M. Eggermont, Stefan Suciu, Stéphane Dalle, Rutger H. T. Koornstra, Leonel Hernandez-Aya, Shahneen Sandhu, Paul Lorigan, Georgina V. Long, Matteo S. Carlino, James Larkin, Dirk Schadendorf
المساهمون: Universitat de Barcelona, Medical oncology, CCA - Cancer Treatment and quality of life
المصدر: Recercat. Dipósit de la Recerca de Catalunya
instname
The New England Journal of Medicine, 378, 1789-1801
New England Journal of Medicine, 378(19), 1789-1801. Massachussetts Medical Society
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Maio, M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P, Ibrahim, N, Marreaud, S, van Akkooi, A C J, Suciu, S & Robert, C 2018, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma ', New England Journal of Medicine, vol. 378, no. 19, pp. 1789-1801 . https://doi.org/10.1056/NEJMoa1802357Test
Dipòsit Digital de la UB
Universidad de Barcelona
The New England Journal of Medicine, 378, 19, pp. 1789-1801مصطلحات موضوعية: 0301 basic medicine, Male, Skin Neoplasms, Medizin, Pembrolizumab, Kaplan-Meier Estimate, Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Disease-Free Survival, Double-Blind Method, Female, Humans, Infusions, Intravenous, Intention to Treat Analysis, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Survival Rate, Gastroenterology, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Immunologic, Monoclonal, 80 and over, Humanized, Adjuvant treatment of cancer, education.field_of_study, General Medicine, Local, 030220 oncology & carcinogenesis, Intravenous, medicine.drug, Tractament adjuvant del càncer, medicine.medical_specialty, Infusions, Population, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, Adjuvants, education, Survival rate, business.industry, Cancer, medicine.disease, 030104 developmental biology, Neoplasm Recurrence, Cutaneous melanoma, business, Placebos (Medicine)
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ae9f22b7acc35569131373f281fa946Test
https://doi.org/10.1056/NEJMoa1802357Test -
4
المؤلفون: Alfonsus J. M. van den Eertwegh, Sandrine Marreaud, Veronica M. Rivas, James Larkin, Jean-Jacques Grob, Leonel Hernandez-Aya, Sven Janssen, Susana Puig, Michele Maio, Alexander C.J. van Akkooi, Stéphane Dalle, Rahima Jamal, Matteo S. Carlino, Ralf Gutzmer, Nageatte Ibrahim, Alexander M.M. Eggermont, Mario Mandalà, Dirk Schadendorf, Stefan Suciu, Piotr Rutkowski, Rutger H. T. Koornstra, Andrew Haydon, Georgina V. Long, Mikhail Lichinitser, Caroline Robert, Shahneen Sandhu, Paolo A. Ascierto, Adnan Khattak, Victoria Atkinson, Christian U. Blank
المصدر: Cancer Research. 78:CT001-CT001
مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, education.field_of_study, business.industry, Hazard ratio, Population, Ipilimumab, Pembrolizumab, Interim analysis, Placebo, Gastroenterology, Oncology, Internal medicine, medicine, Adjuvant therapy, Nivolumab, business, education, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::93d5e0e9ed0f65eb2027f40605f571efTest
https://doi.org/10.1158/1538-7445.am2018-ct001Test